Psoriasis is a unique disease with cutaneous and systemic immunologic alterations [1, 15], and its relationship to the screening tests can be assessed in many ways, such as by the PASI at the time of the test, disease duration, comorbidities, inflammatory markers such as ESR, CRP, and cytokines of the Th17 and Th1 pathways. This evidence concerns the gene ESR1 and psoriasis.